(IN BRIEF) Researchers from the University of Southampton will join the Breast Walk Ever charity event on 8 June 2025 to support Against Breast Cancer and raise funds for vital research into secondary breast cancer. ABC-funded PhD student Grace Hayes … Read the full press release
Posted in Business, Education, Financial, Healthcare, Industrial, Investment, Management, Media, News, Science, Society, Technology, United Kingdom
Tagged ABC events, Against Breast Cancer, bone metastasis, Breast Walk Ever, Cancer Detection, cancer research, charity event, Deborah Parnell, fundraising, fundraising event, Grace Hayes, Hursley, immunology, immunotherapy, miONCO test, PhD student research, Richard Martin, secondary breast cancer, Southampton researchers, University of Southampton, Winchester
(IN BRIEF) The POTOMAC Phase III trial results show that adding Imfinzi to standard BCG induction and maintenance therapy improves disease-free survival (DFS) for patients with high-risk non-muscle-invasive bladder cancer (NMIBC). The combination demonstrated significant benefits over BCG alone, with … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged AstraZeneca, Bacillus Calmette-Guérin, BCG, bladder cancer, cancer treatment, clinical trial, Cristian Massacesi, disease progression, disease-free survival, durvalumab, high-risk bladder cancer, Imfinzi, immunotherapy, Maria De Santis, NMIBC, non-muscle-invasive bladder cancer, Phase III Trial, POTOMAC
(IN BRIEF) Scientists at the University of Southampton have engineered a new type of super-strong antibody, which could significantly enhance immune system responses in cancer patients. By altering the shape and rigidity of antibodies, the team discovered that these modified … Read the full press release
Posted in Business, Education, Financial, Healthcare, Industrial, Investment, Management, News, Science, Technology, United Kingdom
Tagged antibodies, antibody engineering, Cancer Immunotherapy, Cancer Research UK, cancer treatment, disulfide bonds, immune response, immune system, immunotherapy, Isabel Elliott, Ivo Tews, Mark Cragg, Nature Communications, rigid antibodies, structural biology, super-strong antibody, University of Southampton
(IN BRIEF) The University of Glasgow is leading the innovative FOxTROT 5 trial, which is offering elderly colon cancer patients the opportunity to participate in a groundbreaking immunotherapy study. The trial will administer dostarlimab before surgery, targeting a specific type … Read the full press release
Posted in Business, Education, Financial, Healthcare, Industrial, Investment, Management, News, Science, Technology, United Kingdom
Tagged cancer research, cancer treatment, chemotherapy, clinical trial, clinical trial protocol, colon cancer, deficient mismatch repair, dMMR, dostarlimab, Elderly Patients, FOxTROT 5, frail patients, GSK, immunotherapy, partnership, precision oncology, surgery, UK hospitals, University of Birmingham, University of Glasgow, University of Leeds
(IN BRIEF) The MATTERHORN Phase III trial has demonstrated that a perioperative regimen combining AstraZeneca’s Imfinzi (durvalumab) with FLOT chemotherapy significantly improves event-free survival in patients with resectable gastric and gastroesophageal junction cancers compared to standard chemotherapy alone. Interim findings … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged adjuvant, AstraZeneca, clinical trial, Cristian Massacesi, durvalumab, early-stage, EFS, event-free survival, FLOT chemotherapy, gastric cancer, gastroesophageal junction, GEJ cancers, global, Imfinzi, immunotherapy, locally advanced, MATTERHORN, Memorial Sloan Kettering, neoadjuvant, OS, overall survival, pathologic complete response, PCR, Phase III Trial, randomized, resectable, safety profile, tumor regression, Yelena Y. Janjigian
(IN BRIEF) AstraZeneca’s Imfinzi (durvalumab) has received a positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for approval as a monotherapy to treat limited-stage small cell lung cancer (LS-SCLC) in patients whose disease … Read the full press release
Posted in Business, European Union, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged ADRIATIC Phase III trial, AstraZeneca, CHMP, disease progression, durvalumab, EMA, European Medicines Agency, hazard ratio, Imfinzi, immunotherapy, limited-stage small cell lung cancer, LS-SCLC, monotherapy, overall survival, platinum-based chemoradiation therapy, progression-free survival, regulatory review, safety profile, Small cell lung cancer, Suresh Senan, survival outcomes, Susan Galbraith, The New England Journal of Medicine, treatment approval
(IN BRIEF) Researchers from the University of Freiburg have found that triple-negative breast cancer stem cells are invisible to the immune system due to changes in their metabolism. The study discovered that the cells adapt to become undetectable by downregulating … Read the full press release
(PRESS RELEASE) THE HAGUE, 19-Jun-2020 — /EuropaWire/ — The Dutch Research Council (NWO) has announced that six researchers will receive the highest awards in science in the Netherlands. The Spinoza Prize, emphasised on the scientific work and fundamental questions, will … Read the full press release
Posted in Awards, Financial, Healthcare, Netherlands, News, Science, Technology
Tagged Awards, Cancer, chemotherapy, DNA, Eindhoven University of Technology, immunotherapy, laureate, Leiden University, molecular biophysics, NWO, oncology, professor Jan van Hest, Professor Linda Steg, Professor Nynke Dekker, professor Pauline Kleingeld, professor Sjaak Neefjes, professor Ton Schumacher, researchers, RNA molecules, science, Spinoza Prize, Stevin Prize, TU Delft, University of Groningen
The new immunotherapy will be tested in humans as soon as possible (PRESS RELEASE) ZURICH, 8-May-2020 — /EuropaWire/ — University of Zurich researchers have announced a study that is showing how hematopoietic stem cells from a healthy donor can help … Read the full press release
Posted in Education, Healthcare, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged acute leukemia, Acute myeloid leukemia, Alexander Simonis, AML, Antonia M. Müller, blood stem cells, bone marrow, Burkhard Becher, C. Matthias Wilk, Cancer, cancerous hematopoietic stem cells, CAR-T, chemotherapy, Chiara F. Magnani, Christian Münz, Dario Neri, Donal McHugh, ETH Zurich, genetic modification, hematology, Hematopoietic stem cells, immunotherapy, Jonathan D. Kiefer, Juliane Friemel, leukemia, Maries van den Broek, Markus G. Manz, Markus Manz, Nicolás Nuñez, Norman F. Russkamp, oncology, platelets, radiotherapy, red blood cells, Renier Myburgh, Surema Pfister, transplant, University Hospital Zurich, University of Zurich, white blood cells
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?